Abbott has secured FDA approval for its MitraClip system, designed to treat leaky heart valves caused by mitral regurgitation. The device, which has had marketing approval in Europe since 2008, provides a treatment alternative for patients with the condition who are too weak to undergo open-heart procedures.

Full Story:

Related Summaries